Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TNGX | US
-0.06
-0.85%
Healthcare
Biotechnology
30/06/2024
04/10/2024
6.98
7.03
7.14
6.83
Tango Therapeutics Inc. a biotechnology company discovers and develops drugs for the treatment of cancer. Its lead program is TNG908 a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462 an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260 a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348 an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics Inc. has a strategic collaboration with Gilead Sciences Inc. for the discovery development and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
49.4%1 month
90.2%3 months
76.0%6 months
70.4%-
-
3.23
0.15
0.10
-0.91
12.14
-
-129.96M
747.87M
747.87M
-
-148.69
-
36.10
-50.58
11.32
18.00
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.75
Range1M
5.09
Range3M
5.19
Rel. volume
0.35
Price X volume
3.13M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CARGO Therapeutics Inc. Common Stock | CRGX | Biotechnology | 17.77 | 815.72M | -1.44% | n/a | 6.45% |
Adeptus Health Inc | ADPT | Biotechnology | 5.52 | 814.05M | 7.39% | n/a | 93.65% |
Nuvation Bio Inc | NUVB | Biotechnology | 2.41 | 806.82M | 9.05% | n/a | 112.61% |
Immunome Inc | IMNM | Biotechnology | 13.17 | 790.92M | -2.44% | n/a | 1.09% |
89bio Inc | ETNB | Biotechnology | 7.19 | 772.52M | -0.96% | n/a | 5.31% |
Capricor Therapeutics Inc | CAPR | Biotechnology | 21.65 | 765.05M | 31.05% | n/a | 45.32% |
Opthea Limited | OPT | Biotechnology | 4.48 | 746.87M | -2.61% | n/a | -264.65% |
AbCellera Biologics Inc | ABCL | Biotechnology | 2.5 | 736.66M | 0.81% | n/a | 6.49% |
Arbutus Biopharma Corporation | ABUS | Biotechnology | 3.84 | 724.92M | -1.54% | n/a | 6.09% |
Erasca Inc. Common Stock | ERAS | Biotechnology | 2.54 | 717.56M | 0.79% | n/a | 11.96% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.91 | 0.76 | Cheaper |
Ent. to Revenue | 12.14 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 3.23 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 75.95 | 74.67 | Par |
Debt to Equity | 0.15 | -1.82 | Expensive |
Debt to Assets | 0.10 | 0.26 | Cheaper |
Market Cap | 747.87M | 3.73B | Emerging |